MoonLake Immunotherapeutics’ (MLTX) Buy Rating Reaffirmed at BTIG Research

BTIG Research reiterated their buy rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) in a report published on Monday morning,Benzinga reports. BTIG Research currently has a $30.00 target price on the stock.

Other equities analysts also recently issued research reports about the stock. Rothschild & Co Redburn raised shares of MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and raised their price target for the company from $12.00 to $40.00 in a research note on Thursday, March 19th. HC Wainwright increased their price objective on MoonLake Immunotherapeutics from $32.00 to $40.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Oppenheimer raised their target price on MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 24th. Zacks Research raised MoonLake Immunotherapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Finally, The Goldman Sachs Group lowered MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and upped their price target for the company from $8.00 to $10.00 in a research report on Wednesday, January 14th. Nine analysts have rated the stock with a Buy rating, four have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, MoonLake Immunotherapeutics presently has an average rating of “Hold” and a consensus target price of $23.08.

MoonLake Immunotherapeutics Stock Performance

MoonLake Immunotherapeutics stock opened at $16.93 on Monday. The business has a 50 day moving average of $16.87 and a 200-day moving average of $17.13. The company has a market capitalization of $1.21 billion, a P/E ratio of -4.81 and a beta of 1.20. MoonLake Immunotherapeutics has a 1 year low of $5.95 and a 1 year high of $62.75. The company has a debt-to-equity ratio of 0.24, a current ratio of 9.27 and a quick ratio of 9.27.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its earnings results on Wednesday, February 25th. The company reported ($0.92) EPS for the quarter, hitting the consensus estimate of ($0.92). During the same quarter last year, the company earned ($0.72) EPS. On average, equities research analysts predict that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

A number of institutional investors have recently modified their holdings of MLTX. Hsbc Holdings PLC acquired a new stake in shares of MoonLake Immunotherapeutics during the fourth quarter worth $147,000. Virtu Financial LLC acquired a new position in MoonLake Immunotherapeutics in the fourth quarter valued at $166,000. T. Rowe Price Investment Management Inc. bought a new stake in MoonLake Immunotherapeutics during the fourth quarter valued at $47,000. Vident Advisory LLC bought a new stake in MoonLake Immunotherapeutics during the fourth quarter valued at $204,000. Finally, Virtus Investment Advisers LLC grew its holdings in MoonLake Immunotherapeutics by 595.8% during the 4th quarter. Virtus Investment Advisers LLC now owns 17,987 shares of the company’s stock worth $237,000 after acquiring an additional 15,402 shares during the period. 93.85% of the stock is owned by institutional investors.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.